Moreover, studies by Shahbandi et al. showed that the low NOXA expression in senescent tumor cells confers resistance to senolytics, and thus, represents a major barrier against their use as adjuvant cancer treatment to eliminate residual senescent tumor cells28. The gene discussed is PMAIP1; the disease is neoplasm.